Purpose/Requirements:
To support speculative, exploratory, high-risk/high-reward projects with a primary focus on breast cancer. Applications for this award type should challenge existing paradigms, represent a new direction for the PI, and encourage innovation by the incorporation of techniques and approaches not yet well represented in mainstream breast cancer research. We encourage researchers to attempt breakthroughs that, if successful, could be leveraged into more substantial funding. Both established researchers and new investigators (see below) are welcome to apply. Examples of research not responsive to the IDEA are projects that: (1) propose incremental advances for the underlying topic, (2) duplicate the aims of completed or funded research to the PI derived from non-breast cancer studies without incorporating detailed breast cancer-specific justification, (3) overlap in topic and aims with current grant support to the applicant, or (4) represent portions of existing grants or are derived from larger, R01-type projects.
To be maximally responsive to the IDEA funding mechanism, the applicant must either be previously trained and have published in breast cancer or collaborate with an established breast cancer researcher. IDEA applicants are required to explain how the research project is on a “critical path” to substantially advance the topic under investigation.
IDEAs for new investigators: Researchers at a career level beyond postdoctoral training (or equivalent) and less than three years as an independent investigator (e.g., Assistant Professor or equivalent), or entering research from another field, are encouraged to apply for IDEA grants. During the peer review process, the applicant’s prior research history and accomplishments will be rated less stringently than for IDEAs from established investigators.
Project Duration & Budget Caps:
• 18 months maximum duration
• Budget cap for total project direct costs is either $150,000 or $200,000 (higher cap is for projects using animal or human participants). Modified Total Direct Cost base (MTDC); UC campuses receive a maximum institutional F&A of 35% MTDC (25% for off-campus projects). All other institutions are eligible for indirect costs of up to 25% MTDC or the rate established for the institution through a U.S. Department of Health and Human Services negotiated indirect cost rate agreement (or another similarly established rate), whichever is higher.
This is the single most important CBCRP predictor.
Reviewers strongly prefer projects that:
Focus on breast cancer issues specifically affecting California communities
Include California-specific epidemiology, patient populations, environmental exposures, or policy contexts
Engage California-based partners (clinics, communities, public health agencies)
Predictor: Strong California relevance = significantly higher chances of funding.
CBCRP explicitly seeks bold, transformative ideas.
Successful projects often include:
New therapeutic targets or pathways
Novel imaging or diagnostic technologies
Innovative prevention strategies
Cutting-edge omics, computational biology, microenvironment analysis
First-in-concept translational approaches
Predictor: Innovative science with strong rationale, even if risky, is encouraged.
CBCRP is one of the few funders that prioritizes community involvement.
Strong predictors include:
Partnering with community organizations early (planning stages)
Meaningful roles for patient advocates, survivors, and stakeholders
Co-designed research questions & dissemination plans
Addressing inequities in breast cancer outcomes
Predictor: Genuine, integrated community partnership — not tokenism.
CBCRP prioritizes:
Breast cancer health disparities affecting racial/ethnic minorities, low-income groups, rural populations, LGBTQ+ communities
Environmental risk factors (pesticides, endocrine disruptors, pollutants)
Policy-relevant research
Predictor: A proposal addressing structural inequities or environmental causes is highly competitive.
Even for basic science, CBCRP expects:
Defined downstream impact on prevention, diagnosis, or treatment
A realistic trajectory toward future clinical trials or policy translation
Partnerships with clinicians, translational scientists, or public health entities
Predictor: A credible plan linking discovery → patient benefit.
Strong CBCRP proposals have:
1–3 realistic, focused aims
Solid methodology (whether lab-based, clinical, or community research)
Recruitment or sample-access feasibility
Clear endpoints (biomarkers, patient outcomes, behavioral change, exposure measures)
Realistic timeline for a 1–3 year project
Thoughtful risk-mitigation strategies (important for high-risk proposals)
Predictor: Reviewers must believe the project can actually succeed.
Best-performing projects frequently involve:
Oncologists
Epidemiologists
Molecular biologists
Environmental scientists
Community partners
Data scientists
Policy experts
Predictor: Interdisciplinary teams increase translational and community impact.
CBCRP funds both established investigators and new researchers.
Success predictors include:
For established PIs:
Publications in breast cancer or relevant translational fields
Leadership in collaborative research
Demonstrated ability to complete projects
For early-career applicants:
Mentorship structure
Protected time
Clear career-development plan
Predictor: Ability to deliver on the proposed work.
CBCRP carefully evaluates budgets.
Strong applications:
Request appropriate funds for aims (not inflated)
Demonstrate cost-effectiveness
Justify personnel, supplies, community partner compensation, analytic costs
Are aligned with CBPRP’s emphasis on fair compensation for community collaborators
Predictor: A credible, fair, and efficient budget.
| Pitfall | Why It Hurts |
|---|---|
| Weak California focus | Misaligned with CBCRP mission |
| Minimal community engagement | Major red flag for community-based categories |
| Very generic or low-risk science | Not competitive for innovation-driven funding |
| Lack of focus on disparities | Misses a core CBCRP priority |
| Overly ambitious complex projects | Not feasible under CBCRP timelines |
| Poor justification for methodological approach | Weakens reviewer confidence |
| Inadequate stakeholder involvement | Suggests limited real-world impact |
| Budget misalignment | Appears unrealistic or wasteful |
Applications for this award type should challenge existing paradigms, represent a new direction for the PI and encourage innovation by the incorporation of techniques and approaches not yet well represented in mainstream breast cancer research. We encourage researchers to attempt breakthroughs that, if successful, could be leveraged into more substantial funding. Both established researchers and new investigators are welcome to apply.
Sponsor Institute/Organizations: California Breast Cancer Research Program
Sponsor Type: Corporate/Non-Profit
Address: 300 Lakeside Drive, 6th Floor
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Mar 05, 2026
Mar 05, 2026
$200,000
Affiliation: California Breast Cancer Research Program
Address: 300 Lakeside Drive, 6th Floor
Website URL: https://www.cbcrp.org/funding-opportunities/idea/
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.